109 results on '"Russillo, M"'
Search Results
2. Gender differences in microRNA expression in levodopa-naive PD patients
3. Radiological evaluation of response in patients with locally advanced/metastatic soft tissue sarcoma treated with trabectedin.
4. Correction to: Gender differences in microRNA expression in levodopa‑naive PD patients
5. 167P Molecular analysis of gastrointestinal stromal tumor (GIST): The experience of Regina Elena National Cancer Institute
6. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine
7. Magnetic resonance T1w/T2w ratio and voxel-based morphometry in multiple system atrophy
8. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
9. Abstract P4-01-19: Liquid biopsy and re-biopsy: Tracking mutational trajectories in HER2+ breast cancer patients undergoing T-DM1 treatment
10. Progression free survival (PFS) benefit from first line endocrine based therapies in postmenopausal women with HR+ HER2- metastatic breast cancer (MBC) according to different prognostic subgroups: A combined analysis of data from PALOMA 2, MONALEESA 2, MONARCH 3, FALCON, SWOG and FACT trials
11. Abstract P4-21-11: T-DM1 in HER2 positive advanced breast cancer patients: Real world practice from a multicenter observational study
12. 340P - Progression free survival (PFS) benefit from first line endocrine based therapies in postmenopausal women with HR+ HER2- metastatic breast cancer (MBC) according to different prognostic subgroups: A combined analysis of data from PALOMA 2, MONALEESA 2, MONARCH 3, FALCON, SWOG and FACT trials
13. Italian observational study on T-DM1 in HER2 positive advanced breast cancer patients: real world effectiveness and safety
14. Pseudoprogression and MGMT status in glioblastoma patients. implications in clinical practice
15. [Aromatase inhibitors in advanced breast cancer]
16. Role of vacuum assisted biopsy(mammotome) in early detection of breast cancer
17. Endocrinoterapia neoadiuvante nel carcinoma della mammella localmente avanzato
18. F07 - Italian observational study on T-DM1 in HER2 positive advanced breast cancer patients: real world effectiveness and safety
19. Biological markers to predict response to neoadjuvant chemotherapy (NCT) in patients with locally advanced breast cancer (LABC): Ready for prime time?
20. Maintenance bevacizumab after first-line treatment in HER2-negative metastatic breast cancer patients.
21. Outcome of patients (pts) with brain metastases (BMs) from HER2-positive breast cancer (BC) treated with lapatinib plus capecitabine (LC).
22. Individualized administration of capecitabine plus lapatinib in heavily pretreated HER2+ metastatic breast cancer patients: A single-center experience.
23. 4005 Trastuzumab-related cardiotoxicity in the elderly: which role for cardiovascular risk factors?
24. 4012 Adjuvant docetaxel and cyclofosfamide in breast cancer patients over 65 years: compliance and toxicity
25. Dose-escalating study of continuative low dose of oral vinorelbine in patients with advanced breast cancer
26. Changes in HER2 overexpression between primary tumor and autologous metastases: Correlations with clinical and biological features
27. Trastuzumab-related cardiotoxicity in setting outside clinical trials: A mono-institutional experience
28. Capecitabine (X) in elderly patients (pts) with hormone-refractory metastatic breast cancer (MBC)
29. Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study.
30. Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.
31. BEVACIZUMAB-BASED THERAPY RECURRENT MALIGNANT GLIOMA: CORRELATION BETWEEN SERUM VEGF AND RESPONSE TO TREATMENT
32. Trastuzumab in metastatic breast cancer
33. Bone of the hands as unusual metastastatic site of renal cell carcinoma
34. Magnetic resonance T1w/T2w ratio and voxel-based morphometry in multiple system atrophy
35. Effects of gender on cognitive and behavioral manifestations in multiple system atrophy
36. Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer. Efficacy in combination with hormonal therapy
37. Biobanks as an Indispensable Tool in the "Era" of Precision Medicine: Key Role in the Management of Complex Diseases, Such as Melanoma.
38. [Dramatic response to encorafenib plus binimetinib in a patient with leukemoid reaction from metastatic melanoma.]
39. The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world.
40. Bcl-2 family inhibitors sensitize human cancer models to therapy.
41. Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup.
42. Metastatic Melanoma: Liquid Biopsy as a New Precision Medicine Approach.
43. Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma.
44. Correction to: Prognostic value of total metabolic tumour volume and therapy-response assessment by [ 18 F]FDG PET/CT in patients with metastatic melanoma treated with BRAF/MEK inhibitors.
45. Palbociclib plus letrozole induces a complete metabolic response in metastatic breast cancer patient with idiopathic thrombocytopenia.
46. Prognostic value of total metabolic tumour volume and therapy-response assessment by [ 18 F]FDG PET/CT in patients with metastatic melanoma treated with BRAF/MEK inhibitors.
47. Post-Progression Treatments after Palbociclib plus Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer Patients: What Is the Better Choice?
48. Exploring CT Texture Parameters as Predictive and Response Imaging Biomarkers of Survival in Patients With Metastatic Melanoma Treated With PD-1 Inhibitor Nivolumab: A Pilot Study Using a Delta-Radiomics Approach.
49. The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: Early data from a single-institute survey.
50. Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.